{"DataElement":{"publicId":"5748573","version":"1","preferredName":"Trametinib Administered Agent Total Dose","preferredDefinition":"Text describing total dose of Trametinib agent administered.","longName":"TRMB_ADMN_AGT_TT_DS","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5748572","version":"1","preferredName":"Trametinib Agent Administered","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The act of having given something (e.g., a medication or test).","longName":"5748570v1.0:2233610v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5748570","version":"1","preferredName":"Trametinib Agent","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C77908:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib","conceptCode":"C77908","definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CBF0E95-7725-08DA-E053-F662850A669D","latestVersionIndicator":"Yes","beginDate":"2017-04-09","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-09","modifiedBy":"ONEDATA","dateModified":"2017-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CBF0E95-7733-08DA-E053-F662850A669D","latestVersionIndicator":"Yes","beginDate":"2017-04-09","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-09","modifiedBy":"ONEDATA","dateModified":"2017-04-09","changeDescription":"advl1521-PDC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2188705","version":"1","preferredName":"Agent Total Dose","preferredDefinition":"the total dose of an agent.","longName":"AGT_TTL_DOSE","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":"1","maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2207921","version":"1","preferredName":"Total Dose","preferredDefinition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete.:The amount of medicine taken, or radiation given, at one time.","longName":"C25304:C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Total","conceptCode":"C25304","definition":"Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3542-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E53FB579-C11C-0A0E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-09-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-09-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Total dose of Trametinib duri","type":"Preferred Question Text","description":"Total dose of Trametinib during the reporting period:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CBF0E95-774C-08DA-E053-F662850A669D","latestVersionIndicator":"Yes","beginDate":"2017-04-09","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-09","modifiedBy":"CHANGP","dateModified":"2017-04-09","changeDescription":"ADVL1521-PDC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}